We put a lot of hope in the neurological therapy pipeline because—let’s face it—what’s available isn’t all that great. This week, an early-stage trial brings alarming new results for a hotly-anticipated multiple sclerosis therapy that we’re all rooting for. Plus, we’ve got plenty of good eats for Parkinson’s protection, a drug that will de-chronic your…

Ever wondered if you’re really making a difference as a neurologist? Well, let go of that uncertainty right now. We’ve got the data to prove that the world desperately needs you—and will likely continue to need you for decades to come. But that’s not all. We’re also bringing you new tricks to help your patients…

All eyes are on aducanumab, the Biogen drug that has some folks leaping for joy and others scratching their heads. The Alzheimer’s needle is moving elsewhere, too—prepare for a new blood test that’s available right now in clinics across the US (if you don’t have it already), and get ready to open your mind to…

The layers of the Alzheimer’s onion keep peeling back, but we’ve yet to answer the simplest question: What causes it? That may have changed this week, as researchers set their sights on a new mutation that could lead to our best therapies yet. On top of that, we’re still short on therapies for tons of…

Beating a neurological disease—especially the degenerative kind—comes down to getting ahead of it. This week, we’re getting a whole lot closer to that lofty goal thanks to two new tests—one for Alzheimer’s and one for Parkinson’s—that each boast tenfold increases in sensitivity. Plus, we’ve got new neurological benefits of coffee, a debunked link between cannabis…